H. Köppler

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo et al. · The Lancet Oncology · 2016 · 613 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma

Ulrich Kaiser, Irmgard Uebelacker, Ulrich Abel et al. · Journal of Clinical Oncology · 2002 · 139 citations

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, Anna Maria Fink, Raymonde Busch et al. · Blood · 2014 · 117 citations

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)

Rudolf Weide, H. Köppler, Jochen Heymanns et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2007 · 97 citations

Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy

Rudolf Weide, Jochen Heymanns, Annette Pandorf et al. · Lupus · 2003 · 87 citations